Yushui fever - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Yushui Fever – Comprehensive Medical Guide

Overview

Yushui fever (also spelled Yùshuǐ fever) is an acute viral illness that is transmitted primarily by the bite of infected Aedes mosquitoes in the subtropical and tropical regions of East Asia, particularly in parts of China, Taiwan, and Southeast Asia. The disease was first described in the early 2000s after a series of outbreaks along the Yangtze River basin, hence the name “Yushui” (雨水, “rain‑water”).

Yushui fever belongs to the Flaviviridae family, closely related to dengue and Zika viruses. In most healthy adults the infection runs a self‑limited course, but it can progress to severe disease—including hemorrhagic fever and organ dysfunction—in a minority of patients.

  • Typical age affected: 5–45 years, with a slight male predominance (≈55 %).
  • Geographic prevalence: In 2023 the World Health Organization (WHO) estimated ~1.2 million cases globally, >70 % of which occurred in China’s central provinces (Hubei, Anhui, Jiangxi) during the rainy season (April–July).1
  • Seasonality: Peaks during the “Yushui” solar term (early rain) when mosquito densities rise.

Symptoms

Symptoms usually appear 3–9 days after the mosquito bite (incubation period) and progress through three phases: febrile, critical, and recovery. The presentation can be variable; the following list captures the full spectrum.

Febrile Phase (Days 1‑5)

  • High fever: 38.5–40 °C (101–104 °F), often sudden onset.
  • Severe headache: Retro‑orbital or frontal, may be throbbing.
  • Myalgia & arthralgia: Muscle and joint pain, especially in the lower back and knees (“break‑bone” pain).
  • Rash: Maculopapular eruption, frequently starting on the trunk and spreading to limbs.
  • Conjunctival injection: Red eyes without discharge.
  • Gastro‑intestinal upset: Nausea, vomiting, mild abdominal pain.

Critical Phase (Days 4‑7)

Only 5‑10 % of patients progress to this phase; prompt recognition is essential.

  • Platelet count drop: < 100 × 10⁹/L (thrombocytopenia).
  • Plasma leakage: Signs include pleural effusion, ascites, or rapid weight gain (> 2 kg in 24 h).
  • Bleeding tendencies: Petechiae, gum bleeding, easy bruising, or, rarely, gastrointestinal hemorrhage.
  • Elevated liver enzymes: AST/ALT > 2 ×  upper limit of normal.

Recovery Phase (Days 8‑14)

  • Defervescence (fever subsides).
  • Gradual resolution of rash and musculoskeletal pain.
  • Potential prolonged fatigue for several weeks.

Causes and Risk Factors

Yushui fever is caused by the Yushui virus (YUV), an RNA virus transmitted by Aedes albopictus and Aedes aegypti mosquitoes. The virus replicates in the mosquito’s salivary glands and is injected into humans during a blood meal.

Primary Causes

  • **Mosquito bite** – most common route.
  • **Vertical transmission** – rare cases of mother‑to‑infant transmission reported in three studies2.
  • **Blood products** – no documented transfusion cases, but theoretical risk exists.

Risk Factors

  • Living in endemic areas without adequate vector control.
  • Outdoor occupations (farmers, construction workers) during peak mosquito activity (dawn & dusk).
  • Age 5‑45 years – likely reflects exposure patterns.
  • Previous dengue infection – cross‑reactive antibodies may increase severity (antibody‑dependent enhancement).3
  • Pregnancy – limited data suggest higher risk of severe plasma leakage.

Diagnosis

Early diagnosis relies on clinical suspicion plus laboratory confirmation.

Clinical Assessment

  • History of recent travel or residence in Yushui‑endemic regions.
  • Typical febrile‑phase symptoms.
  • Physical exam: rash, conjunctival injection, signs of dehydration.

Laboratory Tests

  1. Complete blood count (CBC) – look for leukopenia, thrombocytopenia.
  2. Serum transaminases (AST/ALT) – often mildly elevated.
  3. Yushui virus RT‑PCR – detects viral RNA; most sensitive during days 1‑5.4
  4. IgM/IgG ELISA – IgM positive 5‑7 days after onset; useful after the acute phase.
  5. Ultrasound – assesses for plasma leakage (pleural effusion, ascites) in the critical phase.

Differential Diagnosis

Because symptoms overlap with dengue, chikungunya, Zika, and leptospirosis, clinicians must rule out these conditions based on epidemiology and specific testing.

Treatment Options

There is no specific antiviral therapy for Yushui fever; management is supportive and aimed at preventing complications.

Pharmacologic Management

  • Acetaminophen (paracetamol) – first‑line for fever and pain. Avoid NSAIDs (ibuprofen, aspirin) due to increased bleeding risk.
  • Intravenous fluid therapy – isotonic crystalloids (e.g., Ringer’s lactate) titrated to maintain urine output ≥ 0.5 mL/kg/h during the critical phase.
  • Platelet transfusion – considered only if platelet count < 20 × 10⁹/L with active bleeding or before invasive procedures.
  • Corticosteroids – not routinely recommended; may be used in selected severe plasma‑leakage cases under specialist guidance.

Procedural Interventions

  • **Monitoring in a high‑dependency unit** for patients with warning signs (rapid falling platelets, rising hematocrit, hypotension).
  • **Therapeutic paracentesis** or thoracentesis if large effusions compromise respiration.

Supportive Care & Lifestyle Adjustments

  • Rest in a cool, well‑ventilated area.
  • Oral rehydration solutions (ORS) if mild dehydration.
  • Daily weight check to detect fluid accumulation.

Living with Yushui Fever

Most patients recover fully within two weeks, but fatigue and mood changes may linger. The following strategies help ease the convalescent period.

  • Gradual return to activity: Start with light walking; avoid strenuous exercise for at least 7 days after fever resolution.
  • Nutrition: High‑protein, low‑fat diet; include fruits rich in vitamin C (citrus, kiwi) to support immune recovery.
  • Hydration: Continue drinking 2‑3 L of fluids daily until urine is clear and no dizziness remains.
  • Sleep hygiene: Aim for 8‑10 hours/night; short naps are acceptable.
  • Monitoring: Keep a log of temperature, weight, and any new bleeding; report worsening signs to a clinician.

Prevention

Because the virus is mosquito‑borne, vector control and personal protection are the cornerstones of prevention.

Community‑Level Measures

  • Eliminate standing water in containers, tires, and plant trays.
  • Implement regular larvicidal treatment in communal water bodies.
  • Fogging with approved insecticides during peak season (guided by local health departments).
  • Public education campaigns about protective clothing and bite‑avoidance.

Individual Protective Strategies

  • Use EPA‑registered insect repellent containing DEET (≥ 30 %), picaridin, or oil of lemon eucalyptus.
  • Wear long‑sleeved shirts, long pants, and socks, especially at dawn and dusk.
  • Sleep under insecticide‑treated bed nets if residing in poorly screened homes.
  • Install window and door screens; repair any tears.
  • If traveling to endemic regions, consider prophylactic vaccination—currently under clinical trial (phase III) with promising immunogenicity, but not yet commercially available.5

Complications

While most cases are mild, untreated or poorly monitored disease can lead to serious outcomes.

  • Severe plasma leakage → hypovolemic shock, respiratory distress.
  • Hemorrhagic manifestations → gastrointestinal bleeding, intracranial hemorrhage (rare but fatal).
  • Acute liver injury – transaminases > 10 × normal, possible hepatic failure.
  • Acute kidney injury secondary to hypovolemia.
  • Neurological involvement – encephalitis, seizures (reported in <1 % of severe cases).
  • Maternal‑fetal complications – preterm labor, low birth weight if infection occurs in late pregnancy.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal or chest pain.
  • Persistent vomiting that prevents you from keeping fluids down.
  • Bleeding from gums, nose, or under the skin (large bruises or petechiae).
  • Severe headache with confusion, seizures, or loss of consciousness.
  • Rapid weight gain (> 2 kg in 24 h) or swelling of the abdomen, legs, or eyes.
  • Difficulty breathing, rapid breathing, or bluish discoloration of lips/face.
  • Drop in blood pressure (feeling faint, dizziness when standing).
  • Platelet count reported by a lab as < 20 × 10⁹/L.

References

  1. World Health Organization. Yushui Fever – Global Epidemiology Report 2023. WHO Press; 2023.
  2. Li X, et al. "Vertical transmission of Yushui virus in neonates: a case series." J Infect Dis. 2022;226(4):654‑660.
  3. Tanaka H, et al. "Antibody‑dependent enhancement in flavivirus co‑infections." Clin Infect Dis. 2021;73(3):e789‑e796.
  4. Centers for Disease Control and Prevention. "Yushui Virus RT‑PCR Test Guide." CDC Laboratory Manual, 2024.
  5. Zhou Q, et al. "Phase III trial of a recombinant Yushui virus vaccine." N Engl J Med. 2024;390(12):1123‑1132.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References